For researchers in the know!
Read editorials detailing cutting edge developments in the field of nanomedicine and see if there are any up and coming conferences you would like to attend. Explore possible careers within the nanomedicine community or put your research on our map and read information about regulatory authorities ensuring right steps are being taken within your research.
Are You New To Nanomedicine?
Information about nanomedicine for people without background knowledge in science is provided. Provides an introduction to nanomedicine, an overview of the nanomedicines currently in clinical use, a glossary of sciencitifc terms often used in nanomedicine and a section on frequently asked questions.
Everything teachers and pupils need to know about Nanomedicine
Fun and simple classroom activities are available for teaching and learning about the key principles of nanotechnology as well as short videos to help with explanations. Up to date nanonews and brief explanations of current research involving nanomedicine are also available.
Welcome to the British Society for Nanomedicine
With the global benefits of the new science of nanomedicine growing each year, the British Society for Nanomedicine has been created to allow open access for industry, academia, clinicians and the public to news and details of ongoing research throughout the UK
The 3rd edition of the Nano World Cancer Day (NWCD), will take place simultaneously in 13 countries including, Austria, Czech Republic, Finland, France, Germany, Greece, Italy, Ireland, Luxembourg, Netherlands, Norway, Portugal, United Kingdom and USA, on the 2nd February 2016.
This event is designed to engage with the general public, clinicians, scientists and the media (radio, TV, press) to raise awareness and improve knowledge about the field of nanomedicine and its range of applications against cancer, from diagnostic to therapeutic perspectives.
The event will take place at 33 Finsbury Square, EC2A 1AG, London, United Kingdom.
For more information and to register please click here
Editors-in-Chief Steve Rannard, Raj Bawa, Si-Shen Feng and Andrew Owen
The Journal of Interdisciplinary Nanomedicine (JOIN) is an international peer-reviewed academic journal that aims to provide truly interdisciplinary nanomedicine research. JOIN is now accepting submissions from all relevant fields to be included in the first issue.
The journal contains evidence-based research and translational outputs with high-level contributions from at least two sciences that are peer-reviewed by multiple reviewers tasked to focus primarily on their specialist areas. Multiple first and/or corresponding author status is encouraged so as to provide transparency and acknowledgment for contribution to multidisciplinary work. The Journal embraces submissions from all relevant fields as applied to early stage scientific developments and studies aimed at the progression of nanomedicines towards the clinic, which include engineering, science and medicine, especially materials sciences, life science, clinical science, intellectual property, regulatory issues and policy considerations. JOIN contains original research papers, editorials, review articles, technical notes, and letters to the editor about matters that may benefit the wider readership. Advances that are progressing to application through consolidation of multiple areas of expertise are especially encouraged. Core areas of particular interest include applications of new materials and biological concepts, targeted delivery, molecular biomaterials and nanotechnology in diagnostics, pharmacology, pharmaceutics, toxicology, and clinical outcomes.
For further details please look here
Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes
A major unmet clinical need is a universal method for subcellular targeting of bioactive molecules to lysosomes. Moody et al have recently pubblished an article in "Molecular Therapy" where they have described a general method that uses receptor crosslinking to trigger endocytosis and subsequently redirect trafficking of receptor:cargo complexes from their expected route, to lysosomes. By incubation of plasma membrane receptors with biotinylated cargo and subsequent addition of streptavidin to crosslink receptor:cargo–biotin complexes, the authors have achieved rapid and selective lysosomal targeting of transferrin, an anti-MHC class I antibody, and the clinically approved anti-Her2 antibody trastuzumab. These data suggest that crosslinking could be exploited for a wide range of target receptors, for navigating therapeutics through the endolysosomal pathway, for significant therapeutic benefit.
For further details please look here